Clinical Efficacy of Antiplatelet Therapy Based on CYP2C19 Gene Detection in Patients With Acute Ischemic Stroke
Objective To probe the necessity of gene testing about CYP2C19 which is required to further standardize and accurately implement antiplatelet therapy in acute ischemic stroke.Methods A retrospective study was conducted on 102 patients with acute ischemic stroke admitted to the department of neurology,Fujian Provincial Geriatric Hospital from January 2022 to February 2023,all of whom were treated with clopidogrel antiplatelet therapy.All of them were divided into two groups according to whether CYP2C19 gene was performed.There were 63 patients in control group and 39 patients in observation group,the observation group underwent genetic testing and adjusted antiplatelet drugs according to the genetic results.The incidence of progressive stroke was observed in 2 groups.Results There was no statistically significant difference between two groups in baseline comparison(P>0.05).The CYP2C19 gene of clopidogrel has 6 metabolic types,the main mutations of CYP2C19 gene of clopidogrel are CYP2C19*2 and CYP2C19*3,especially the former.The incidence of progressive stroke in the observation group was 10.26％,lower than 26.98％in the control group,and the difference was statistically significant(P<0.05).Conclusion CYP2C19 gene detection can predict clopidogrel resistance,to a certain extent,CYP2C19*2 and CYP2C19*3 are prone to clopidogrel resistance.
万方数据
维普
